Standard BioTools (LAB) Expected to Announce Quarterly Earnings on Tuesday

Standard BioTools (NASDAQ:LAB) is projected to post its Q4 2025 results after the market closes on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $18.50 million for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Standard BioTools Stock Performance

Standard BioTools stock opened at $1.13 on Monday. The business’s fifty day moving average is $1.40 and its two-hundred day moving average is $1.34. The firm has a market cap of $434.56 million, a P/E ratio of -3.32 and a beta of 1.29. Standard BioTools has a 52 week low of $0.92 and a 52 week high of $1.72.

Insider Buying and Selling

In other Standard BioTools news, Director Casdin Partners Master Fund, L bought 150,000 shares of the company’s stock in a transaction on Thursday, December 4th. The stock was bought at an average price of $1.45 per share, for a total transaction of $217,500.00. Following the transaction, the director owned 72,100,000 shares of the company’s stock, valued at approximately $104,545,000. The trade was a 0.21% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have acquired 7,900,000 shares of company stock worth $10,318,000. 23.16% of the stock is currently owned by insiders.

Institutional Trading of Standard BioTools

Hedge funds have recently added to or reduced their stakes in the business. Cibc World Markets Corp acquired a new position in Standard BioTools in the fourth quarter valued at about $25,000. Aigen Investment Management LP acquired a new stake in shares of Standard BioTools during the fourth quarter worth about $28,000. EntryPoint Capital LLC bought a new position in shares of Standard BioTools during the 4th quarter valued at about $31,000. CIBC Asset Management Inc acquired a new position in shares of Standard BioTools in the 4th quarter valued at approximately $33,000. Finally, Russell Investments Group Ltd. increased its stake in Standard BioTools by 2,989.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock worth $33,000 after purchasing an additional 24,211 shares in the last quarter. Institutional investors and hedge funds own 53.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LAB. TD Cowen reduced their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research report on Wednesday, November 5th. Wall Street Zen lowered shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Standard BioTools in a research note on Thursday, January 22nd. Finally, Zacks Research raised shares of Standard BioTools to a “hold” rating in a report on Thursday, December 11th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Standard BioTools has a consensus rating of “Reduce” and a consensus target price of $1.35.

Standard BioTools Company Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.